Jane Royalty

442 total citations
20 papers, 350 citations indexed

About

Jane Royalty is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Jane Royalty has authored 20 papers receiving a total of 350 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Jane Royalty's work include Advanced Breast Cancer Therapies (6 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Drug Transport and Resistance Mechanisms (3 papers). Jane Royalty is often cited by papers focused on Advanced Breast Cancer Therapies (6 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Drug Transport and Resistance Mechanisms (3 papers). Jane Royalty collaborates with scholars based in United States, Singapore and United Kingdom. Jane Royalty's co-authors include Palaniappan Kulanthaivel, P. Kellie Turner, Stephen D. Hall, Alan Y. Chiang, Y. Anne Pak, James A. Bacon, Joseph V. Bonventre, R Stoltz, Jennifer Witcher and Sitra Tauscher‐Wisniewski and has published in prestigious journals such as Cancer Research, Clinical Pharmacology & Therapeutics and Journal of Endocrinology.

In The Last Decade

Jane Royalty

19 papers receiving 343 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jane Royalty United States 11 88 88 87 69 58 20 350
Jagadeesh Aluri United States 16 138 1.6× 82 0.9× 107 1.2× 16 0.2× 76 1.3× 50 636
Chris Walker United States 13 88 1.0× 54 0.6× 138 1.6× 23 0.3× 175 3.0× 22 628
Pengfei Xu China 9 118 1.3× 81 0.9× 22 0.3× 24 0.3× 25 0.4× 19 450
Masaaki Takemura Japan 12 259 2.9× 82 0.9× 201 2.3× 57 0.8× 28 0.5× 18 588
Anthony V. Serritella United States 8 90 1.0× 132 1.5× 157 1.8× 48 0.7× 15 0.3× 30 467
Yoshiharu Horie Japan 11 105 1.2× 23 0.3× 101 1.2× 55 0.8× 51 0.9× 18 423
Shinpei Nonen Japan 18 286 3.3× 96 1.1× 82 0.9× 58 0.8× 64 1.1× 36 707
Jan Beneš Czechia 12 192 2.2× 72 0.8× 31 0.4× 85 1.2× 12 0.2× 40 814
Masahisa Goto Japan 10 169 1.9× 37 0.4× 25 0.3× 73 1.1× 58 1.0× 14 392
Wolfgang Uhl Germany 9 93 1.1× 39 0.4× 37 0.4× 37 0.5× 27 0.5× 17 340

Countries citing papers authored by Jane Royalty

Since Specialization
Citations

This map shows the geographic impact of Jane Royalty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Royalty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Royalty more than expected).

Fields of papers citing papers by Jane Royalty

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Royalty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Royalty. The network helps show where Jane Royalty may publish in the future.

Co-authorship network of co-authors of Jane Royalty

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Royalty. A scholar is included among the top collaborators of Jane Royalty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Royalty. Jane Royalty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chiang, Alan Y., et al.. (2023). Abemaciclib does not increase the corrected QT interval in healthy participants. Clinical and Translational Science. 16(9). 1617–1627. 5 indexed citations
2.
Turner, P. Kellie, Stephen D. Hall, Sonya C. Chapman, et al.. (2020). Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer. Drug Metabolism and Disposition. 48(9). 796–803. 17 indexed citations
3.
Turner, P. Kellie, et al.. (2018). Abstract P1-10-14: Abemaciclib tablet formulation is bioequivalent to capsules. Cancer Research. 78(4_Supplement). P1–10. 1 indexed citations
4.
Turner, P. Kellie, Y. Anne Pak, James A. Bacon, et al.. (2018). Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clinical Pharmacology & Therapeutics. 105(5). 1187–1195. 74 indexed citations
5.
Small, David S., et al.. (2016). Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib. European Journal of Clinical Pharmacology. 72(5). 563–572. 1 indexed citations
6.
Small, David S., et al.. (2016). Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 36(7). 749–756. 4 indexed citations
7.
Chappell, Jill, et al.. (2016). Abstract CT152: Food effect on the pharmacokinetics of 200-mg abemaciclib in healthy subject. Cancer Research. 76(14_Supplement). CT152–CT152. 8 indexed citations
8.
Kulanthaivel, Palaniappan, Daruka Mahadevan, P. Kellie Turner, et al.. (2016). Abstract CT153: Pharmacokinetic drug interactions between abemaciclib and CYP3A inducers and inhibitors. Cancer Research. 76(14_Supplement). CT153–CT153. 17 indexed citations
9.
Small, David S., Wei Zhang, Jane Royalty, et al.. (2015). A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State. Journal of Cardiovascular Pharmacology and Therapeutics. 20(5). 483–489. 8 indexed citations
10.
Cannady, Ellen A., Aktham Aburub, Chris Ward, et al.. (2015). Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [13C8]‐evacetrapib as a tracer. Journal of Labelled Compounds and Radiopharmaceuticals. 59(6). 238–244. 12 indexed citations
11.
Lowe, Stephen L., Conrad J. Wong, Jennifer Witcher, et al.. (2014). Safety, tolerability, and pharmacokinetic evaluation of single‐ and multiple‐ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. The Journal of Clinical Pharmacology. 54(9). 968–978. 81 indexed citations
12.
Kam, Pieter‐Jan de, Wen‐Lin Luo, Larissa Wenning, et al.. (2013). The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin. Platelets. 25(7). 480–487. 3 indexed citations
13.
14.
Boudes, Pol, Sheela Sitaraman, George R. Lankas, et al.. (2011). Pharmacokinetics and muscle distribution of AT2220, a pharmacological chaperone of acid-glucosidase, in healthy volunteers. Molecular Genetics and Metabolism. 102(2). S4–S4. 1 indexed citations
15.
Luo, Wen‐Lin, Tami Crumley, David L. Ebel, et al.. (2010). Single Therapeutic and Supratherapeutic Doses of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, Do Not Prolong the QTcF Interval in Healthy Volunteers. The Journal of Clinical Pharmacology. 50(11). 1273–1279. 2 indexed citations
16.
Lai, Eseng, Jules I. Schwartz, Aimée Dallob, et al.. (2010). Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects. Platelets. 21(3). 191–198. 14 indexed citations
17.
Dishy, Victor, Fang Liu, David L. Ebel, et al.. (2009). Effects of Aspirin When Added to the Prostaglandin D2 Receptor Antagonist Laropiprant on Niacin‐Induced Flushing Symptoms. The Journal of Clinical Pharmacology. 49(4). 416–422. 16 indexed citations
18.
Schwartz, Jules I., Aimée Dallob, Patrick Larson, et al.. (2008). Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX‐2 Versus COX‐1 in Healthy Subjects. The Journal of Clinical Pharmacology. 48(6). 745–754. 35 indexed citations
19.
Pequignot, Edward, Deborah Panebianco, Paul Lupinacci, et al.. (2006). Lack of Effect of Aprepitant on Hydrodolasetron Pharmacokinetics in CYP2D6 Extensive and Poor Metabolizers. The Journal of Clinical Pharmacology. 46(7). 792–801. 12 indexed citations
20.
Taylor, George T., et al.. (1986). Social behaviour and testicular activity of juvenile rats. Journal of Endocrinology. 110(3). 533–537. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jagadeesh Aluri Breakdown of academic impact, for papers by Chris Walker Breakdown of academic impact, for papers by Pengfei Xu Breakdown of academic impact, for papers by Masaaki Takemura Breakdown of academic impact, for papers by Anthony V. Serritella Breakdown of academic impact, for papers by Yoshiharu Horie Breakdown of academic impact, for papers by Shinpei Nonen Breakdown of academic impact, for papers by Jan Beneš Breakdown of academic impact, for papers by Masahisa Goto Breakdown of academic impact, for papers by Wolfgang Uhl
Rankless by CCL
2026